欧州医薬品庁(EMA)が、2つのキメラ抗原受容体遺伝子改変T細胞(CAR-T)療法について、EUにおける承認を支持【EMA】

血液腫瘍に対するtisagenlecleucel(商品名Kymriah)とaxicabtagene ciloleucel (同Yescarta)
First two CAR-T cell medicines recommended for approval in the European Union

The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union (EU). Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) are advanced therapies for blood cancer. They belong to a new generation of personalised cancer immunotherapies that are based on collecting and modifying patients’ own immune cells to treat their cancer.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*